mediated Pro binding and recognition as a substrate of the factor Xa-factor Va catalytic complex (27) (28) (29) . Recent mutagenesis studies in which proexosite I residues were shown to play a critical role in factor Va acceleration of prethrombin 1 (Pre 1) activation support the importance of this site in substrate recognition (30) . In Pro and Pre 1, exosite II is covered by the covalently linked fragment 2 domain (25) . Whether exosite II is expressed as a result of passive dissociation of F2 following cleavage at Arg 271 -Thr 272 or by a conformational change affecting affinity for F2 is not known. Delineating the pathway of expression of exosites I and II is important to understanding the roles of these sites in the mechanism of factor Va acceleration of Pro activation, regulation of the activation pathway, and regulation of physiological interactions of the Pro activation intermediates and thrombin.
Previous studies of exosite I interactions of Pro activation species do not provide a consistent view of the pathway of expression of exosite I. Exosite I was accessible on human meizothrombin des-fragment 1 (MzT(-F1)) for binding of thrombomodulin and an anti-exosite I antibody, whereas exosite I on human Pro, Pre 2, and MzT did not bind these macromolecules (31) . In studies of the bovine proteins, however, binding of fluorescein-labeled hirudin [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] (hirugen) to Pro and Pre 1 was undetectable, while Pre 2 bound the peptide with similar affinity as thrombin (32) . MzT and MzT(-F1) both bound the peptide with 2-8 fold higher affinity than Pre 2, suggesting that either peptide bond cleavage in Pro results in activation of exosite I (32 The differential expression of exosite I affinity on the Pre 1 activation intermediates is thought to play a role in the activity of factor Va to regulate the rate and direction of the Pre 1 activation pathway. In the companion paper (33) , these studies are extended to the Pro activation intermediates to investigate the effect of the F1 domain in modulating activation of exosite I.
EXPERIMENTAL PROCEDURES
Protein purification and characterization-Human Pro, factor X, factor Xa, and thrombin were purified and characterized as described previously (34, 35 F2) ), and the formation of the ternary complex,
Effect of F2 on binding of hirudin peptides to Pre 2-
The observed fluorescence changes of the labeled hirudin peptide in Scheme I can be described as a function of the concentration of the two fluorescent complex species relative to probe alone, as given by: fold higher affinity of the peptide for Pre 1 compared to Pro (Fig. 3B , Table I ). The results suggested that removal of F1 either caused a conformational change in exosite I on Pre 1 that increased affinity for hirudin peptides, or that the F1 domain on Pro interfered with peptide binding to exosite I. This observation is addressed further in the companion manuscript (33) .
Binding of fragment 2 to [6F]FPR-thrombin, [5F]FPR-thrombin, and prethrombin 2-
Interactions of F2 with exosite II on thrombin and Pre 2 were characterized in equilibrium binding experiments with thrombin labeled at the active site with 6- ) with MzT(-F1) showed a similar dissociation constant of 65±13 nM for the unlabeled peptide (Fig. 6B) . The affinity of the labeled peptide for MzT(-F1) was indistinguishable from that for thrombin (Table I) Table I . Titrations were performed and analyzed as described under Experimental Procedures. Titrations were performed and analyzed as described under Experimental Procedures. Table I . Titrations were performed and analyzed as described under Experimental Procedures. Table I . Titrations were performed and analyzed as described in Experimental
Binding of hirudin peptides to prethrombin 2 and the prethrombin 2-fragment 2 complex-
Procedures. Table 1 Parameters determined for binding of hirudin [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] peptides to prethrombin 1, the prethrombin 1 activation intermediates, and products.
The dissociation constants (K D ), stoichiometric factors (sites), and maximum fluorescence changes (∆F max /F o ) determined for hirudin [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] peptides from direct and competitive titrations, and ternary complex analysis are listed. Titrations were performed and data analyzed as described in Experimental Procedures. Figure 1 
